 |
市場調查報告書
商品編碼
1728478
乾癬性關節炎市場:KOL的洞察KOL Insight - Psoriatic Arthritis |
||||||
本報告全面分析了銀屑病關節炎 (PsA) 的現有和新興治療策略，為不斷發展的治療格局提供了寶貴的見解。報告強調了TNF抑制劑的持久作用以及對IL-17和IL-23抑制劑日益增長的偏好，尤其是在皮膚和眼部症狀突出的病例中。此外，報告也探討了由於療效提高和易用性增強，從舊療法轉向新型IL-23抑制劑的趨勢。透過關鍵意見領袖 (KOL) 的專家意見，報告全面概述了這些治療轉變如何塑造PsA管理的未來。
關鍵問題解答
- 目前推薦的乾癬性關節炎 (PsA) 治療方法是什麼？
- 抗IL17和抗IL23等新療法有何不同？
- JAK抑制劑和TYK2抑制劑等口服藥物在目前的治療模式中處於什麼位置？
- 哪些患者因素對乾癬性關節炎（PsA）的治療選擇影響最大？
- 支付方壓力將如何影響KOL的決策？
- 抗TNF和JAK抑制劑的生物相似藥將如何影響PsA的治療方案？
- 哪些仿製藥最受KOL的關注？
- 在研藥物需要具備哪些優勢才能與市場領導者競爭？
- 目前PsA的診斷和治療有哪些差距？
- 未來3-5年，PsA的治療模式預計將如何變化？
領導品牌
|
|
|
部分參與專家名單
- 德州大學西南醫學中心臨床醫學教授，達拉斯長老會醫院風濕病科聯合主任德州
- 哈佛醫學院布萊根婦女醫院臨床風濕病學聯合主任，蒙彼利埃大學醫學教授，麻薩諸塞州波士頓
- 紐約阿爾伯特愛因斯坦醫學院醫學院臨床副教授
- 英國利茲大學風濕病學教授，利茲NIHR生物醫學研究中心主任
- 荷蘭阿姆斯特丹聯合醫療中心風濕病學和臨床免疫學主任，教授
- 法國蒙彼利埃大學蒙彼利埃中心風濕病學教授，風濕病學主任，骨關節醫學和外科主任
方法
"治療趨勢" 報告透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，就關鍵疾病領域的當前和未來治療前景進行總結。我們根據嚴格的篩選標準，精心挑選關鍵意見領袖 (KOL)，這些標準涵蓋全球聲譽、臨床專業知識以及在治療領域的影響力。每次訪談都附有精心設計的討論指南。這些指南由我們與關鍵意見領袖合作制定，並由行業專家進行同行評審，以確保所提問題全面且與當前市場動態相關。每份報告發布後，我們都會持續進行12個月的市場監測，並及時提供來自關鍵意見領袖的重大新聞事件、市場變化和市場發展動態的更新。
我們的報告有何特別之處？
FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供詳細且可操作的洞察。我們深厚的行業知識使我們能夠為您提供相關且有價值的洞察，幫助您掌握新興趨勢並有效應對複雜課題。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家獨家訪談和數據，以及持續的市場監測，確保您全面了解市場動態。我們的報告涵蓋 40 多個活躍疾病領域，匯集醫生情報（包括 KOL 洞察和定量醫生調查），以及行業專家對醫療事務、數位醫療、銷售與市場營銷、市場准入及其他領域問題的看法，助您做出更明智的數據驅動決策，在快速變化的行業中保持競爭力。
This report provides a comprehensive analysis of the current and emerging treatment strategies for Psoriatic Arthritis (PsA), offering valuable insights into the evolving therapeutic landscape. It highlights the enduring role of TNF inhibitors and the rising preference for IL-17 and IL-23 inhibitors, particularly in cases with significant skin or ocular symptoms. Additionally, the report explores the shift from older therapies to newer IL-23 inhibitors, driven by their improved efficacy and ease of use. Through expert opinion from key opinion leaders (KOLs), this report offers a comprehensive overview of how these treatment shifts are shaping the future of PsA management.
Key Questions Answered:
- 1. What are the preferred current treatments for Psoriatic Arthritis (PsA)?
- 2. How do newer treatments like anti-IL17s and anti-IL23s compare to each other?
- 3. Where do oral therapies like JAK and TYK2 inhibitors stand in the current treatment landscape?
- 4. What patient factors most significantly influence PsA therapy choices?
- 5. How do payer pressures shape the decisions of key opinion leaders (KOLs)?
- 6. What impact will biosimilar anti-TNFs and JAK inhibitors have on the PsA treatment algorithm?
- 7. Which late-stage drug candidates are generating the most interest among KOLs?
- 8. What must pipeline drugs demonstrate to compete with market leaders?
- 9. What are the current gaps in PsA diagnosis and management?
- 10. How is the PsA treatment landscape expected to change in the next three to five years?
Key Brands:
|
|
|
Partial List of Participating Experts:
- Clinical Professor in the Department of Internal Medicine, UT Southwestern Medical Center, Co-Director of the Division of Rheumatology at Presbyterian Hospital, Dallas, TX
- Co-Director, Clinical Rheumatology, Brigham and Women's Hospital and Professor of Medicine, Harvard Medical School, Boston, MA
- Clinical Associate Professor, Department of Medicine, Albert Einstein College of Medicine, NY
- Director of the Leeds NIHR Biomedical Research Centre, Professor of Rheumatology, University of Leeds, Leeds, UK
- Professor, Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC, Amsterdam, Netherlands
- Professor of Rheumatology, Head of the department of Rheumatology, Head of the medical and surgical bones and joint departments, Montpellier University, CHU Montpellier, France
Methodology:
Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
